Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

By Jared Kaltwasser

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

This Week in Managed Care: December 26, 2015

December 26th 2015

This Week in Managed Care: December 26, 2015

This week The American Journal of Managed Care offers a special episode of highlights from the American Society of Hematology's annual meeting, including sessions on newly approved treatments, how the move to pay-for-performance affects hematologists, and the increasing role of patient-reported outcomes.

December 25th 2015

Most-Viewed Videos from AJMC for the Year 2015

Surabhi Dangi-Garimella, PhD

Top 10 videos from The American Journal of Managed Care's Summit and Insight programs.

December 23rd 2015

Rivaroxaban Safe and Effective in Cancer Patients With Thrombosis

Laura Joszt, MA

Although rivaroxaban was approved by the FDA in 2012, there has remained a knowledge gap about how it works with cancer patients. A recent study found that the therapy is safe and effective when used among patients with cancer.

December 22nd 2015

OB-GYN Groups Say Insurers' Genetic Testing Rules Limit Access to Care

Mary K. Caffrey

The statement from the obstetricians and gynecologists said that there aren't enough certified genetic counselors to meet demand. In a statement, the groups said this will limit access to care if patients must wait for assistance before ordering tests.

December 22nd 2015

Top 10 Articles from Evidence-Based Oncology for the Year 2015

Surabhi Dangi-Garimella, PhD

The most read articles in The American Journal of Managed Care's Evidence-Based Oncology ranged from personal narratives to healthcare policy issues that impact the broader population.

This Week in Managed Care: December 19, 2015

December 19th 2015

This Week in Managed Care: December 19, 2015

This week in managed care, Martin Shkreli, CEO of Turing Pharmaceuticals was arrested on charges of fraud; new research find that drug costs continue to take up a larger share of healthcare spending; and 3 healthcare experts take a look at how to fix the 340B drug pricing program.

December 18th 2015

Merck's Pembrolizumab Receives Approval for Expanded Indications

Pembrolizumab has been approved as first-line treatment for patients with unresectable or metastatic melanoma.

December 18th 2015

What We're Reading: Taxpayers Spending Millions on Expensive Generic Drugs

What we're reading, December 18, 2015: HHS report finds generic drug prices rising faster than inflation; UnitedHealthcare's real-time drug approval tool; and government overcharged by private Medicare Advantage plans.

December 18th 2015

Progress Toward Healthy People 2020: CDC Report Claims Reduction in Cancer Incidence

Surabhi Dangi-Garimella, PhD

Results of an analysis of 2012 cancer incidence and survival from various cancer registries, published in CDC's Morbidity and Mortality Weekly Report, indicates reduced incidence of overall cancer across the United States.

December 18th 2015

FDA Seeks Nationwide Ban on Letting Minors Use Tanning Beds

Mary K. Caffrey

Eleven states already ban minors from using tanning beds, and most states have other restrictions such as requiring a parent's permission.

December 17th 2015

Report Provides an Update on the 340B Drug Pricing Program

Surabhi Dangi-Garimella, PhD

A new report by the Berkeley Research Group provides numbers on Medicare Part B spending by 340B entities, especially for oncology drugs.

December 17th 2015

Need to Lower Drug Costs, Not the Size of the Donut Hole, for Medicare Beneficiaries With Cancer

Surabhi Dangi-Garimella, PhD

A study in the Journal of Clinical Oncology predicts financial stress on Medicare Part D beneficiaries on oral anticancer medicines, even after the expected closing of the donut hole in 2020.

December 16th 2015

Kadcyla and Opdivo Too Expensive for NICE

NICE rejects promising oncology agents once again, citing high drug cost.

December 16th 2015

FDA Updates: Oncology

Surabhi Dangi-Garimella, PhD

Several new FDA approvals and research advances in oncology have the potential for improved outcomes among cancer patients.

December 16th 2015

Managed Care Updates: Oncology

Surabhi Dangi-Garimella, PhD

Updates on screening age recommendations for mammograms, CDC report on a decline in smoking rates in the country, and regulation of laboratory-developed tests.

Dr Michael Kolodziej Outlines Ways to Reform 340B

December 15th 2015

Dr Michael Kolodziej Outlines Ways to Reform 340B

There are 3 potential solutions for reforming the 340B drug pricing program, according to Michael Kolodziej, MD, national medical director of oncology solutions in the Office of the Chief Medical Officer at Aetna.

December 15th 2015

Choosing Wisely: Eliminating Unnecessary Biopsies

Surabhi Dangi-Garimella, PhD

A retrospective analysis of phase 1 oncology studies that used biopsy-derived pharmacodynamic biomarkers, could not draw a correlation between subsequent drug development and biopsy sample collection.

December 15th 2015

The Struggle Between Oncology Care Cost and Value

Joseph Alvarnas, MD

While cost is an important component of value, it tells only a small part of the cancer care story. By focusing on issues of payment and cost alone, we miss our opportunity to engage cancer care stakeholders in the process of creating a more effective system of care.

December 15th 2015

Patient Access to Oncology Care in ACA Exchange Plans

Caroline F. Pearson Deirdre B. Parsons, MPP, MPH, MS

This article describes provider networks and benefit design-including deductibles, cost-sharing, and maximum out-of-pocket limits-for oncology care in 2015 health insurance exchanges.

December 15th 2015

Healthcare Leaders Offer Solutions for Reforming 340B in New Issue of Evidence-Based Oncology

Depending on one's point of view, the 340B prescription drug program keeps safety net hospitals afloat or serves as a profit center at the expensive of community providers. Three leading voices-Rena M. Conti, PhD; Peter B. Bach, MD, MAPP; and Michael Kolodziej, MD; recommend reforms in the new issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care.

December 15th 2015

PrecisionFDA Launched With Promise of Transparency and Quality Care

Surabhi Dangi-Garimella, PhD

The FDA, today, launched precisionFDA, a cloud-based platform that members can utilize to access and share data sets, analysis pipelines, and bioinformatics tools.

December 15th 2015

ACCC ICLIO meeting

Surabhi Dangi-Garimella, PhD

At the first annual conference of the Institute for Clinical Immuno-Oncology on October 1, 2015, in Philadelphia, the discussion revolved around integrating immuno-oncology into clinical practice and programs that assist with patient access to these treatments.

December 15th 2015

COA Payer Summit

Surabhi Dangi-Garimella, PhD

Providers and payers came together to discuss challenges and share success stories as they adapt to the changing healthcare realm.

December 14th 2015

Measuring Financial Toxicity in Cancer Patients

Pauline Lee, PharmD Jonas A. de Souza, MD

With the rising costs of cancer care, evidence-based tools can help physicians screen patients for financial toxicity.

December 14th 2015

Eliminating a Barrier to Cancer Care through Universal Fair Access to Oral Chemotherapy Medications

Christopher Hansen

The advocacy affiliate of the American Cancer Society, the American Cancer Society Cancer Action Network, is working across the country to pass and implement strong oral chemotherapy fairness laws to help ensure cancer patients have access to the recommended course of treatment without added out-of-pocket costs based on how their drug is administered.

December 14th 2015

The Financial Impact of Cancer Care: Implications and Potential Solutions

Veena Shankaran, MD, MS

Addressing the financial burden of cancer treatment requires efforts at the policy, payer, and clinic level, and implementation of these strategies, in clinical practice, requires commitment from various stakeholders.

December 14th 2015

Impact of Oral Parity: A Personal Story

Christopher Hansen

Oral chemotherapy ensured improved quality of life for a young, stage 3 pancreatic cancer patient.

December 14th 2015

Healthcare Transparency in Need of Academic Vigilance

Surabhi Dangi-Garimella, PhD

A report by STAT has found that a majority of institutions conducting clinical trials fail to report their results to the website ClinicalTrials.gov.

December 14th 2015

What We Need to Know About Bladder Cancer and Its Treatment

There is, currently, an unmet need in bladder cancer, a disease expected to be responsible for 16,000 deaths in 2015.

December 14th 2015

What We're Reading: Public Health Initiatives Are Underfunded in the US

What we're reading, December 14, 2015: public health initiatives are underfunded despite being a big return on investment; the FDA repeatedly approved the cancer drug Afinitor without proof it extended life; and a nurse may have exposed patients in a maternity wing to tuberculosis.

...

114 115 116 117 118 119 120 121 122

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions